IL139967A - Beta-alanine derivatives and pharmaceutical compositions containing the same - Google Patents

Beta-alanine derivatives and pharmaceutical compositions containing the same

Info

Publication number
IL139967A
IL139967A IL13996799A IL13996799A IL139967A IL 139967 A IL139967 A IL 139967A IL 13996799 A IL13996799 A IL 13996799A IL 13996799 A IL13996799 A IL 13996799A IL 139967 A IL139967 A IL 139967A
Authority
IL
Israel
Prior art keywords
beta
pharmaceutical compositions
same
compositions containing
alanine derivatives
Prior art date
Application number
IL13996799A
Other languages
English (en)
Other versions
IL139967A0 (en
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of IL139967A0 publication Critical patent/IL139967A0/xx
Publication of IL139967A publication Critical patent/IL139967A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13996799A 1998-05-28 1999-05-28 Beta-alanine derivatives and pharmaceutical compositions containing the same IL139967A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8706498P 1998-05-28 1998-05-28
PCT/US1999/011924 WO1999061421A1 (en) 1998-05-28 1999-05-28 A NOVEL VLA-4 INHIBITOR: oMePUPA-V

Publications (2)

Publication Number Publication Date
IL139967A0 IL139967A0 (en) 2002-02-10
IL139967A true IL139967A (en) 2005-11-20

Family

ID=22202907

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13996799A IL139967A (en) 1998-05-28 1999-05-28 Beta-alanine derivatives and pharmaceutical compositions containing the same

Country Status (30)

Country Link
US (1) US6495525B1 (is)
EP (1) EP1082302B1 (is)
JP (1) JP2002516309A (is)
KR (1) KR100636713B1 (is)
CN (1) CN1148350C (is)
AT (1) ATE256659T1 (is)
AU (1) AU764108B2 (is)
BG (1) BG65021B1 (is)
CA (1) CA2333656C (is)
CZ (1) CZ298413B6 (is)
DE (1) DE69913687T2 (is)
DK (1) DK1082302T3 (is)
EA (1) EA002988B1 (is)
EE (1) EE04639B1 (is)
ES (1) ES2211096T3 (is)
HU (1) HUP0102255A3 (is)
IL (1) IL139967A (is)
IS (1) IS5737A (is)
MX (1) MXPA00011774A (is)
NO (1) NO317990B1 (is)
NZ (1) NZ509199A (is)
PL (1) PL198189B1 (is)
PT (1) PT1082302E (is)
SI (1) SI1082302T1 (is)
SK (1) SK285280B6 (is)
TR (1) TR200100190T2 (is)
UA (1) UA65623C2 (is)
WO (1) WO1999061421A1 (is)
YU (1) YU75500A (is)
ZA (1) ZA200007300B (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ES2221227T3 (es) * 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
AU757873B2 (en) * 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6525069B1 (en) * 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EE200200070A (et) 1999-08-13 2003-04-15 Biogen, Inc. Raku adhesiooni inhibiitorid
EA004673B1 (ru) 1999-12-28 2004-06-24 Пфайзер Продактс Инк. Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
ATE524441T1 (de) 2000-12-28 2011-09-15 Daiichi Seiyaku Co Vla-4-inhibitoren
WO2005009992A1 (ja) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. シクロヘキサンカルボン酸類
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
US7685367B2 (en) * 2006-03-08 2010-03-23 Microsoft Corporation Multi-cache cooperation for response output caching
AU2007281090A1 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗vla-4抗体
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1149971B (it) 1979-06-11 1986-12-10 Syntex Inc Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4725583A (en) 1985-01-23 1988-02-16 Abbott Laboratories Functionalized peptidylaminoalcohols
US4826815A (en) 1985-05-17 1989-05-02 Abbott Laboratories Renin inhibiting compounds
DK163689A (da) 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
ATE131471T1 (de) 1989-12-22 1995-12-15 Commw Scient Ind Res Org An fette gebundene aminosäuren, peptide oder deren derivate
CA2043741C (en) 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
CA2071674C (en) 1991-06-21 2003-08-19 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5352667A (en) 1991-11-22 1994-10-04 Ofer Lider Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them
AU3420693A (en) 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
DE4212304A1 (de) 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
IL102646A (en) 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
JPH08505628A (ja) 1993-01-08 1996-06-18 田辺製薬株式会社 ペプチド型細胞接着阻害薬
US5314902A (en) 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
EP0695547B1 (en) 1993-04-09 2001-08-08 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5434188A (en) 1994-03-07 1995-07-18 Warner-Lambert Company 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
CN1478472A (zh) * 1996-07-25 2004-03-03 ¸ 细胞粘连抑制剂

Also Published As

Publication number Publication date
JP2002516309A (ja) 2002-06-04
UA65623C2 (en) 2004-04-15
BG65021B1 (bg) 2006-12-29
EE200000698A (et) 2002-06-17
EP1082302B1 (en) 2003-12-17
NO20006023L (no) 2001-01-17
EA002988B1 (ru) 2002-12-26
EA200001236A1 (ru) 2001-06-25
HUP0102255A2 (hu) 2001-11-28
ATE256659T1 (de) 2004-01-15
IS5737A (is) 2000-11-28
BG105060A (en) 2001-08-31
CZ298413B6 (cs) 2007-09-26
CA2333656C (en) 2008-07-29
NZ509199A (en) 2003-10-31
CA2333656A1 (en) 1999-12-02
SI1082302T1 (en) 2004-06-30
DE69913687D1 (de) 2004-01-29
IL139967A0 (en) 2002-02-10
ES2211096T3 (es) 2004-07-01
CZ20004425A3 (en) 2001-05-16
CN1307561A (zh) 2001-08-08
CN1148350C (zh) 2004-05-05
HK1035726A1 (en) 2001-12-07
NO317990B1 (no) 2005-01-17
TR200100190T2 (tr) 2001-05-21
AU764108B2 (en) 2003-08-07
WO1999061421A1 (en) 1999-12-02
US6495525B1 (en) 2002-12-17
PL198189B1 (pl) 2008-06-30
SK285280B6 (sk) 2006-10-05
DK1082302T3 (da) 2004-04-26
KR100636713B1 (ko) 2006-10-20
PT1082302E (pt) 2004-04-30
AU4219299A (en) 1999-12-13
EE04639B1 (et) 2006-06-15
ZA200007300B (en) 2002-02-27
EP1082302A1 (en) 2001-03-14
HUP0102255A3 (en) 2001-12-28
NO20006023D0 (no) 2000-11-28
SK18102000A3 (sk) 2001-07-10
KR20010043906A (ko) 2001-05-25
DE69913687T2 (de) 2004-10-07
YU75500A (sh) 2002-12-10
PL344440A1 (en) 2001-11-05
MXPA00011774A (es) 2002-10-17

Similar Documents

Publication Publication Date Title
IL139967A0 (en) β-ALANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
HUP0200347A2 (en) N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use
HUP0103283A3 (en) Pyrazinone protease inhibitors, pharmaceutical compositions containing them and use of the compounds
AU6523396A (en) Novel farnesyl transferase inhibitors, preparation thereof and pharmaceutical compositions containing said inhibitors
HUP0105077A3 (en) Serine protease inhibitors and pharmaceutical compositions containing them
AU4543696A (en) Novel farnesyl transferase inhibitors, preparation thereof and pharmaceutical compositions containing same
AU4722796A (en) Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same
AU1912197A (en) New inhibitors of metalloprotease, process for preparing them and pharmaceutical compositions containing them
HUP0100669A3 (en) Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof
HUP9802315A3 (en) Thrombin inhibitors, process for producing them and use of them for producing pharmaceutical compositions
AU6382396A (en) Novel inhibitors of collagenase-1 and stromelysin-i metallop roteases, pharmaceutical compositions comprising same and me thods of their use
IL119466A (en) Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
AU5329096A (en) Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
HUP9801227A3 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors and their use
AU2208401A (en) Inhibitors of complement activation, their preparation and use
HUP9900390A3 (en) Serine protease inhibitors, and pharmaceutical compositions containing them
AU6617596A (en) Cyclo-oxygenase inhibitor and amidine derivative salts, their preparation process, their use as medicaments, and pharmaceutical compositions containing them
AU1031697A (en) Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
HUP0101899A3 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes, pharmaceutical compositions comprising thereof and their use
IL117247A0 (en) Pharmaceutical compositions comprising protease inhibitors and quinoxalines
AU2001261519A1 (en) Methods of affecting laminin 5 processing
AU2002223313A1 (en) Protease inhibitors and their pharmaceutical uses
IL112423A0 (en) Inhibitors of serine proteases, their preparation and pharmaceutical compositions containing them
CO5070670A1 (es) Taloproteinasas de arilsulfonamidas y estatinas

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees